Anastrozole vs Naltrexone
FDA Approved vs FDA Approved
avoid Mechanism-based · 75% Both Anastrozole and Naltrexone carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Anastrozole Naltrexone
Weight 293.37 Da 341.40 Da
Half-life ~40-50 hours ~4 hours
Type Nonsteroidal aromatase inhibitor (triazole derivative) Opioid antagonist (C20H23NO4)
Key Benefits
Anastrozole
01 Potent reduction of circulating estradiol levels (70-80% at standard dose)
02 Prevents gynecomastia during testosterone or anabolic steroid cycles
03 Reduces estrogen-driven water retention and bloating
04 Helps control estrogen-related blood pressure elevation
05 Oral dosing with long half-life allows flexible scheduling (EOD or E3D)
06 Reversible inhibition allows estrogen recovery after discontinuation
07 Well-characterized pharmacokinetics with decades of clinical data
Naltrexone
01 Broad anti-inflammatory and immunomodulatory effects via OGF-OGFr axis upregulation
02 Reduction in pro-inflammatory cytokines (TNF-alpha, IL-6, IL-12) through TLR4 antagonism
03 Compensatory upregulation of endogenous endorphins and enkephalins (200-300% increase)
04 Improved immune regulation and rebalancing of Th1/Th2/Th17 responses
05 Reduction in chronic pain through central and peripheral opioid system modulation
06 Potential improvement in mood, anhedonia, and overall well-being via endorphin enhancement
07 Extremely well-tolerated with minimal side effects at low doses
08 Low cost, especially as compounded LDN formulation
Side Effects
Anastrozole
Joint pain, stiffness, or dryness (from reduced estrogen-mediated joint lubrication)
Hot flashes or flushing
Fatigue and general malaise
Mood changes (flat affect, irritability, or low mood)
Decreased libido (when estrogen is suppressed too aggressively)
Headache
Naltrexone
Vivid dreams or unusually intense dreaming - the most frequently reported side effect, typically diminishes over 1-2 weeks
Initial sleep disruption or insomnia during the first week of treatment
Mild nausea, particularly during the first few days
Transient headache during dose initiation or titration
Contraindications
Known hypersensitivity to anastrozole or any excipients
Premenopausal women (not indicated and potentially harmful to reproductive function)
Pregnancy or breastfeeding (teratogenic risk)
Severe hepatic impairment
Pre-existing severe osteoporosis or high fracture risk
Concurrent use with tamoxifen or estrogen-containing therapies
Current use of opioid medications or active opioid dependence (must be opioid-free 7-10 days minimum)
Acute hepatitis or severe hepatic impairment (primarily relevant at full dose)
Known hypersensitivity to naltrexone
Anticipated need for opioid pain medication (e.g., upcoming surgery - discontinue LDN 3-7 days prior)
Research Evidence
Anastrozole Naltrexone
Status FDA Approved FDA Approved
References 5 studies 5 studies
Latest — 2023
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.